Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BetaFIT: Beta Cell Imaging After FMT in T1D
NCT05622123Phase 2Unknown
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-NODAGA-Exendin-4 in type 1 diabetes mellitus (T1D), sponsored by Radboud University Medical Center. Primary endpoint: Correlation between residual beta cell mass and function at 1 year. Status: unknown.
02
Drugs
68Ga-NODAGA-Exendin-4
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05622123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05622123.